QuantCapitol. Congressional Trading Intelligence

Updated 2026-11-05 08:10 UTC · Public disclosure record

OGNTICKER

Organon & Co.

INSUFFICIENT DATA stock

Congress has disclosed 0 buys and 2 sells of OGN (Organon & Co.) in official financial disclosures, each linked to its original filing. A transparency record — not investment advice.

Activity Congressional Activity

0
Buy
2
Sell
-2
Net
1
Active politicians
Price & congressional trades
Buy Sell

Fundamentals · FY2026 Valuation

Standard valuation multiples from SEC-reported GAAP financials (trailing twelve months), each compared to the median for Health. We use reported GAAP, not forward or adjusted earnings, so our figures can sit higher than sites that do — especially for companies with falling profit. Relative context — not a target price or investment advice.

P/E
17.06
▼ cheaper than Health (median 29.7)
how it's calculated
P/E = price ÷ earnings per share
$13.84 ÷ $0.81 = 17.06
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.
P/B
3.05
▼ cheaper than Health (median 4.4)
how it's calculated
P/B = price ÷ book value per share
$13.84 ÷ $4.54 = 3.05
Based on GAAP trailing-twelve-month financials (SEC filings) and the latest close. Other sites may show a different multiple when they use forward (projected) or non-GAAP adjusted figures instead of reported GAAP — for a company with volatile profit those can differ in either direction from the GAAP figure shown here.

Legislation Related Legislation

Recent bills in this stock's sector (Health). Sector-level context from Congress.gov — a bill names a policy area, not this company specifically.

BillTitlePolicy areaLatest action
HR 10887 Protecting Consumer Access to Generic Drugs Act of 2026 Health 2026-10-22
HR 10874 Medicare Low Income Subsidy Equality Act of 2026 Health 2026-10-22
HR 10858 CARE for Blood Cancer Act of 2026 Health 2026-10-22
HR 10810 National Patient Safety Board Act of 2026 Health 2026-10-15
HR 10824 Stroke Education and EMS Care Improvement Act of 2026 Health 2026-10-15

2 trades Recent Congressional Trades

Two things to watch per trade: the disclosure lag (how many days passed before the trade was made public) and the price move in that window (how the stock moved during those non-public days). A sell followed by a price drop, or a buy followed by a rise, means well-timed trading — visible here in the open. Note: the Score measures how notable a trade is, not whether it made money — the price move is shown for context and isn't part of it.

PoliticianChamberTypeOwnerDateDisclosure lagPrice move
in that
window
AmountScoreSource
Kevin Hern House SELL ◆ insider convergence Joint · Hern Family Foundation 2026-08-05 0 days 0.0% $1K–$15K
0.1% of NW
98.7 ↗ filing
Kevin Hern House SELL ◆ insider convergence Self · Hern Family Revocable Trust 2026-08-05 0 days 0.0% $1K–$15K
0.1% of NW
98.7 ↗ filing

Corporate insiders · SEC Form 4 Insider Activity

What the company's own officers and directors did in OGN — open-market purchases and sales from SEC Form 4 filings (option exercises, grants and tax withholding are excluded). This is context for the congressional activity above, never a buy/sell signal, and the two datasets are kept separate on purpose. Does convergence mean anything? →

2
Congress trades with insider convergence
0
…with insider divergence
11
Insider open-market trades

Of the congressional trades in OGN, 2 coincided with corporate insiders moving the same way within 60 days, and 0 with insiders moving the opposite way. This is co-occurrence only — whether it carries any edge is tested honestly on the convergence page.

DateInsiderRoleTypeSizeSource
2026-08-05 Drinane Juliana Papa Other SELL $200K ↗ EDGAR
2026-05-06 Holzbaur Lynette Other SELL $353K ↗ EDGAR
2026-05-06 Holzbaur Lynette Other BUY $353K ↗ EDGAR
2025-11-12 COX CARRIE SMITH Director BUY $502K ↗ EDGAR
2025-05-14 COX CARRIE SMITH Director BUY $101K ↗ EDGAR
2025-05-07 Falcione Aaron C-suite BUY $48K ↗ EDGAR
2025-05-06 Karp Daniel Other BUY $29K ↗ EDGAR
2025-05-06 Weaver Kirke Other BUY $74K ↗ EDGAR
2025-05-05 Ali Kevin C-suite BUY $299K ↗ EDGAR
2025-05-05 WALSH MATTHEW M C-suite BUY $101K ↗ EDGAR
2024-02-22 Weaver Kirke Other BUY $50K ↗ EDGAR

Combined timeline — Congress & insiders

Both sets of trades on one timeline, newest first, so you can see when they lined up. Congress vs ◆ insider.

DateWhoTypeSize
Congress 2026-08-05 Kevin Hern SELL $1K–$15K
Congress 2026-08-05 Kevin Hern SELL $1K–$15K
◆ insider 2026-08-05 Drinane Juliana Papa Other SELL $200K
◆ insider 2026-05-06 Holzbaur Lynette Other SELL $353K
◆ insider 2026-05-06 Holzbaur Lynette Other BUY $353K
◆ insider 2025-11-12 COX CARRIE SMITH Director BUY $502K
◆ insider 2025-05-14 COX CARRIE SMITH Director BUY $101K
◆ insider 2025-05-07 Falcione Aaron C-suite BUY $48K
◆ insider 2025-05-06 Karp Daniel Other BUY $29K
◆ insider 2025-05-06 Weaver Kirke Other BUY $74K
◆ insider 2025-05-05 Ali Kevin C-suite BUY $299K
◆ insider 2025-05-05 WALSH MATTHEW M C-suite BUY $101K
◆ insider 2024-02-22 Weaver Kirke Other BUY $50K

FAQ Common questions

How much has Congress traded OGN?

0 disclosed buys and 2 sells of OGN (Organon & Co.) appear in official congressional financial disclosures.

Is it legal for members of Congress to trade OGN?

Members of Congress may trade stocks but must disclose it under the STOCK Act. QuantCapitol tracks those public disclosures for transparency — nothing here is an accusation of wrongdoing or investment advice.

Where does this data come from?

Official US House Clerk and Senate electronic financial disclosures. Every trade links back to its original filing so you can verify it yourself.

About this data. Sourced from official House Clerk and Senate eFD financial disclosures (Senate via a maintained community mirror — see project documentation). Transaction amounts are reported as ranges, not exact figures. Interest scores, consensus labels, and backtested performance are proprietary analytical calculations based on public data and are not investment advice. Backtested performance is a hypothetical simulation, not actual portfolio performance.